Assessing Risk Factors for End-Stage Renal Disease in Kidney Cancer

Patients who undergo treatment for renal cell carcinoma (RCC) have a 10-times greater risk of end-stage renal disease (ESRD) compared with healthy people, according to a study presented at the 2022 International Kidney Cancer Symposium: North America.

“ESRD causes decreased quality of life for the patient and entails high treatment costs. Treatment of RCC may increase the risk of ESRD,” the investigators wrote.

To conduct this analysis, Sven Lundstam, MD, PhD, and colleagues assessed 215 patients with RCC and subsequent ESRD and compared them with 9299 patients with RCC only. The populations of interest were identified in the National Swedish Kidney Cancer Registry from 2005 to 2014 and linked with the Swedish Renal Registry and the National Patient Registry.

The results showed that the 10-year cumulative incidence of ESRD after RCC was 2.5 %, which was 10-times higher than in the control population. The analysis demonstrated that significant risk factors for ESRD were male sex (hazard ratio (HR), 1.5; 95% CI, 1.1-2.1), T2-4 versus T1 (HR, 1.4; 95% CI, 1.01-1.92), diabetes (HR, 1.9; 95% CI, 1.3-2.7), hypertension (HR, 1.9; 95% CI, 1.4-2.6), and chronic kidney disease stage I-IV (HR, 15.5; 95% CI, 8.6-27.9).

Source : Lundstam S, Akerlund J, Holmberg E, Ljungberg, B, Stendahl M, Bergdahl A. Risk factors for end stage renal disease after treatment of renal cell carcinoma. Poster 14. Presented at the 2022 IKCS: North America; November 4-5, 2022; Austin, Texas.